Prakash S, Chang T M
Artificial Cells and Organs Research Centre Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Artif Cells Blood Substit Immobil Biotechnol. 1998 Jan;26(1):35-51. doi: 10.3109/10731199809118945.
In our earlier reports we have introduced a new method for urea removal in renal failure. This is based on the oral administration of polymeric artificial cells containing nonpathogenic genetically engineered E. coli DH5 cells to renal failure rats. This resulted in the lowering of systemic uremic urea level to normal range without elevation of ammonia. The present article deals with the safety study of this approach. Microscopic study follows changes in microcapsule morphology with time are described. Two parameters, the body weight of the renal failure rats and, the survival for of the renal failure rats receiving microcapsules containing genetically engineered E. coli DH5 cells are discussed in this article. Result shows that there is no significant difference between the weight profile of uremic rats receiving oral therapy and normal control rats. Also the treated group of uremic rats survived longer than the untreated uremic rats.
在我们早期的报告中，我们介绍了一种治疗肾衰竭时去除尿素的新方法。该方法基于给肾衰竭大鼠口服含有非致病性基因工程大肠杆菌DH5细胞的聚合人工细胞。这使得全身性尿毒症尿素水平降至正常范围，而氨水平未升高。本文探讨了该方法的安全性研究。描述了微观研究中微胶囊形态随时间的变化。本文讨论了两个参数，即肾衰竭大鼠的体重以及接受含有基因工程大肠杆菌DH5细胞微胶囊的肾衰竭大鼠的存活情况。结果显示，接受口服治疗的尿毒症大鼠的体重变化与正常对照大鼠之间没有显著差异。此外，接受治疗的尿毒症大鼠组的存活时间比未治疗的尿毒症大鼠更长。
